Universal Genetic Testing for All Breast Cancer Patients

Area of Science:

• Genetics
• Oncology
• Preventive Medicine

Background:

• Women with pathogenic BRCA1/2 mutations have increased breast cancer risk and earlier onset.
• Awareness of BRCA1/2 status enables timely preventive strategies like chemoprevention or prophylactic surgery.
• Current guidelines recommend BRCA1/2 testing for women with a family history of relevant cancers.

Purpose of the Study:

• To evaluate the role of genetic testing, particularly multigene panels, in hereditary breast cancer risk assessment.
• To address the debate surrounding the accuracy of current genetic testing guidelines for breast cancer patients.
• To explore the implications of multigene panel testing, including challenges with variants of unknown significance and management strategies.

Main Methods:

• Review of studies on BRCA1/2 mutations and breast cancer risk.
• Analysis of the utilization and impact of multigene panel testing.
• Examination of current guidelines for genetic testing in breast cancer.

Main Results:

• Multigene panels are increasingly used due to falling costs and discovery of new risk genes.
• Studies suggest current guidelines may miss a significant number of patients with pathogenic variants.
• There are challenges in managing results from multigene panels, especially concerning moderate penetrance genes and variants of unknown significance.

Conclusions:

• Genetic testing, especially multigene panels, is crucial for identifying hereditary breast cancer risk.
• Current guidelines for genetic testing may require revision to improve accuracy and patient identification.
• Further research is needed on risk management and clinical decision-making following multigene panel testing.